Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949790 | 1.00 | LDHA (0.44) | LDHARAB9ATDP1EPHX2FAAH | |
| SCHEMBL17818355 | 0.83 | LMNA (0.43) | LDHARAB9ATDP1EPHX2FAAH | |
| SCHEMBL10154247 | 0.82 | CACNB4 (0.49) | LDHAEPHX2KMT2ARAF1PARP1 | |
| SCHEMBL13247062 | 0.80 | LDHA (0.41) | LDHARAB9ATDP1EPHX2FAAH | |
| SCHEMBL20357270 | 0.77 | EPHX2 (0.47) | LDHAEPHX2FAAHGAAAR | |
| SCHEMBL20357347 | 0.75 | AR (0.45) | EPHX2FAAHARRAF1TNKS | |
| SCHEMBL29861506 | 0.72 | RAB9A (0.35) | LDHARAB9AEPHX2GAAKMT2A | |
| SCHEMBL27002902 | 0.72 | RAB9A (0.35) | LDHARAB9AEPHX2GAAKMT2A | |
| SCHEMBL16494965 | 0.71 | PTGS1 (0.32) | — | |
| SCHEMBL14630694 | 0.70 | EPHX2 (0.58) | RAB9AEPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | LDHA 4103/4885RAB9A 1891/4885TDP1 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.